Analytical Data
-
基因名
CLN6
- Application
-
别名
CLN6; Ceroid-lipofuscinosis neuronal protein 6; Protein CLN6
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NWW5
-
表达区间
1-311aa
-
氨基酸序列
MEATRRRQHLGATGGPGAQLGASFLQARHGSVSADEAARTAPFHLDLWFY FTLQNWVLDFGRPIAMLVFPLEWFPLNKPSVGDYFHMAYNVITPFLLLKL IERSPRTLPRSITYVSIIIFIMGASIHLVGDSVNHRLLFSGYQHHLSVRE NPIIKNLKPETLIDSFELLYYYDEYLGHCMWYIPFFLILFMYFSGCFTAS KAESLIPGPALLLVAPSGLYYWYLVTEGQIFILFIFTFFAMLALVLHQKR KRLFLDSNGLFLFSSFALTLLLVALWVAWLWNDPVLRKKYPGVIYVPEPW AFYTLHVSSRH
-
分子量
62.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLN6 is a protein associated with the neuronal ceroid lipofuscinoses (NCLs), a group of inherited neurodegenerative disorders predominantly affecting children. The CLN6 gene, located on chromosome 15, encodes a protein involved in lysosomal function and cellular homeostasis. Mutations in CLN6 lead to the accumulation of lipofuscins, indicative of lysosomal dysfunction, resulting in progressive neurodegeneration. Understanding the structure and function of CLN6 is crucial for elucidating the pathophysiological mechanisms underlying NCLs, which currently have no effective treatments. Research into recombinant CLN6 protein aims to facilitate the study of its interactions within cellular pathways and potential therapeutic interventions. By producing and characterizing this protein, scientists can explore its role in lysosomal signaling, investigate the effects of specific mutations, and develop targeted strategies to mitigate disease progression. Furthermore, recombinant CLN6 may serve as a valuable tool for high-throughput screening of drug candidates and for studying potential gene therapies. Overall, the investigation of CLN6 recombinant protein is pivotal for advancing our understanding of NCLs and for paving the way toward innovative treatments for affected individuals.
